Research

Persons from across Canada are being invited to participate in the IMAGINE research study. The IMAGINE Network is investigating the interactions between inflammation, microbiome, diet and mental health in patient with IBD (Crohn’s disease or ulcerative colitis) or irritable bowel syndrome (IBS). IMAGINE is also studying whether new therapies (fecal transplants, diet, probiotics, cognitive behaviour therapy) have the potential to transform the management of IBD and IBS and their associated mental health issues.
 
You may be eligible to participate in this study if you have been diagnosed by your physician with Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), including ulcerative colitis or Crohn’s disease, or are a healthy individual without gastrointestinal symptoms.

Visit www.imaginespor.com for more information and to find a recruitment site near you.

The Exclusive Enteral Nutrition (EEN) in Crohn’s Disease study is the first clinical study to investigate the combined use of a nutritional formula with Corticosteriods (CS) in order to decrease the activity of Crohn’s Disease (CD) and improve quality of life. Exclusive Enteral Nutrition has been used to induce remission in pediatric cases of Crohn’s Disease, however its use in adults is much less studied. This is the first pilot study to assess the use of EEN together with CS as a means of inducing remission in adults. We think EEN+CS will be more effective than CS alone in inducing remission and that a short course of CS in tandem with nutritional formula will have a similar efficacy than the standard course of CS, with a reduced number of adverse events. We also would like to test whether nutritional formula will lead to beneficial changes in the intestinal bacteria, gastrointestinal transit and inflammatory burden.

Who is Eligible?
Adults ages 18-75 diagnosed with CD who are flaring and are about to start Prednisone prescribed by their doctor.

Who is Not Eligible?
Unfortunately, we are not able to accept patients with the following criteria:
-Treated with antibiotics or probiotics in the last 30 days
- Used prednisone in the last 30 days
- Currently using EEN
- Short Gut
- Started or changed immunosuppressant or biologic medication in the last 90 days
- Started or changed 5-ASA medication in last 30 days
- Pregnancy or lactation

For more information about the study and what to expect if you are able to participate, please see the brochure here.

Principal Investigator Dr. Ines Pinto-Sanchez, McMaster University
This study has been reviewed by the HiREB.

To participate, please contact
Teresa Balart, MD
Phone: 905-525-9140 ext 22278
Email: balartm@mcmaster.ca

This research is looking at the experiences of young women living with an ostomy as a result of Inflammatory Bowel Disease, looking at the decision-making process up to surgery and actual lived experience of having an ostomy. If you are interested in participating an interview will be arranged at your convenience and take approximately one to two hours.  

Who is eligible?  
Young women between 19-25 living with an ostomy for any length of time.

Interested in participating? Contact Ashley Cark 
Email clarkash@uvic.ca 
Phone 1-250-812-8908

Researcher:
Ashley Clark MA,
University of Victoria, Social Dimensions of Health.

Supervisor/Primary Investigator:
Dr. Andre Smith
Associate Professor, Sociology, University of Victoria.

The human body contains ten bacterial cells for every human cell. This vast, largely unexplored bacterial community, known as the microbiome, has been linked to gastrointestinal health and disease. In the case of inflammatory bowel disease (IBD), it is thought that the immune system may be responding inappropriately to the microbiome. Therefore, it has been hypothesized that changing the microbiome may be an effective treatment for IBD. One way to accomplish this is using Fecal Microbiota Transplantation (FMT), an innovative investigational treatment that has proven effective in the treatment of C. difficile infection.

The purpose of this study is to determine whether FMT is similarly safe and effective in the treatment of mild-to-moderate Crohn’s disease. During FMT, a fecal preparation from a carefully screened, healthy stool donor is transplanted into the colon of the patient. There are multiple routes of administration. We will use both in this study. 

Patients will receive a total of eight FMT/placebo treatments in the study. Patients receiving FMT will be assigned a single donor. The first will be given by colonoscopy at week zero, followed by seven others given by capsules taken by mouth each week. At week eight, patients are unblinded and a follow up colonoscopy is performed. Patients who were initially randomized to placebo can go on to have FMT in the open label phase of the study.
 
Who is eligible to participate?
Patients with mild to moderate Crohn’s disease
Recruiting 126 patients at three Canadian centres (Edmonton, Calgary and Hamilton)
 
To register for this study or for more information, please contact:

Edmonton Contacts
Dr. Dina Kao: dkao@ualberta.ca
Dr. Gina Vavek: gina.vavek@albertahealthservices.ca
Phone: 780-492-5313
 
Calgary Contacts
Dr. Humberto Jijon: Humberto.jijon2@ucalgary.ca
Gurmeet Bindra: gkbindra@ucalgary.ca
Phone: 403-210-7013 or 403-399-9790
 
Hamilton Contact
Melanie Wolfe: wolfe@hhsc.ca

Do you have Crohn's or Colitis? Are you between 16-21 years old?

Seeking individuals diagnosed with inflammatory bowel disease to participate in an online study looking at what promotes and diminishes quality of life of teens and young adults with inflammatory bowel disease. We will be offering a chance for a e-gift card for some lucky winners. Participants must be from the ages of 16 to 21 years of age and fluent in English. The study involves completing 3 online surveys over the course of 2 months. 

To learn more and participate, please click on the following link:
 https://queensu.qualtrics.com/jfe/form/SV_9LAPoqN3gypvb7v 

This study has been approved by The Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (HSREB)

To find out more information about this study, please contact:

Dr. Dean A. Tripp
Associate Professor in the departments of Psychology, Anesthesiology and Urology
Queen's University, Kingston, Ontario 
Email: dean.tripp@queensu.ca

Julia Moreau and Adam Sunavsky
Department of Psychology
Queen’s University, Kingston, Ontario
Julia Moreau Email: 14jmm11@queensu.ca

Patients with ulcerative colitis (UC) may undergo colectomy due to a variety of reasons. Ileal-pouch anal anastomosis is often offered to these patients. Unfortunately the pouch commonly develops inflammation, known as pouchitis, which is the most common complication of this procedure and occurs in approximately 50% of patients, with the majority of these patients having multiple episodes.

Enrolling now for Fecal Microbiota Transplant (FMT) for Patients with Active Pouchitis. The study focuses on use of fecal microbiota transplantation for treatment of pouchitis. The study objectives are to learn about a) if alteration of the microbiota in pouchitis helps improve disease symptoms; and b) understand the changes that occur in the gut bacteria during fecal transplantation. This is a randomized controlled trial of fecal microbiota transplantation versus placebo for treatment of pouchitis.

Who can participate?
1. Be 18 or over and be able to give informed consent.
2. Have symptoms of active pouchitis.
3. Have evidence of active pouchitis in screening pouchoscopy.

Qualified Participants Receive:
1. Study-related care from gastroenterologist including screening pouchoscopy and final pouchoscopy.
2. Once weekly FMT enemas for at least 6 weeks.
3. Compensation for parking.

This study has been reviewed by the Hamilton Integrated Research Ethics Board. Project ID #4702. 

To register for this study or for more information, please contact:
Mr. Peter Habashi: habashp@hhsc.ca

The number of COVID-19 cases has increased rapidly in the past few days and several emergency measures have been taken at the national and international levels to prevent transmission of the virus.

The aim of this project is to study the level of knowledge related to the pandemic, the perception of the risk of being contaminated, the prevention measures taken by adolescents and young adults, and the impact on their life.

Who can participate? You can help us if you:
1. A teenager or young adult between 14 and 22 years old residing in Canada
2. Be able to read and write French or English.
3. Have access to the internet to complete the questionnaire.

If you are interested in completing the online survey, please enter this link into your web browser. https://jantchou.com/covid19world/

What's in it for you?
This questionnaire will allow you to assess your level of knowledge about COVID-19 and we will provide you more information about this. Answers will be available at the end of the questionnaire. You will also help us improve prevention measures for the COVID-19 for adolescents and young adults.

This study has been approved by the CHU Sainte-Justine, Montréal, Québec, Ethics Board (REB# 2020-2864)

To find out more information about this study or to volunteer, please contact:
Xin Yu Yang
Email: jantchoulab@gmail.com

Principal Investigator: Prévost JANTCHOU, M.D., Ph.D., M.B.A
Associate Professor, Gastro-Hépatologie et Nutrition Pédiatriques
CHU Sainte-Justine, Montréal (Qc), Canada

Are you someone living with chronic conditions who can tell us which self-management questions are good to ask?

We are conducting an anonymous and confidential online survey that asks different self-management questions. Input from the survey will help us design the questionnaire to assess patients’ ability to live with chronic health conditions.

The aim of the study is to improve chronic condition management by developing a patient-centred measure of chronic condition self-management that will become the primary tool for both clinical care and research.

Eligibility:

1. Must be 18 years of age or older and have access to internet
2. Live with 1 or more chronic conditions (includes mental and physical)
3. Must be able to read/speak English

Qualified Participants Receive:
You will have the chance to enter your email address to be entered in a draw to win one of four $100 Amazon gift cards.

To learn more and participate, please click on the following link (The study is in English only):
https://surveys.dal.ca/opinio/s?s=55372​

The study has been approved by the Nova Scotia Health Authority Research Ethics Board #1025263

To find out more information about this study or to volunteer, please contact:
Email: prismcc@dal.ca

Principal Investigator: Dr. Tanya Packer
School of Occupational Therapy, Dalhousie University

You are being invited to participate in a completely anonymous research study because you have had Inflammatory Bowel Disease (‘IBD’; either Crohn’s disease or Ulcerative Colitis) and may be contemplating pregnancy, are currently pregnant or have recently been pregnant. This survey is part of a larger registry study currently being conducted by Sinai Health System. 

The aim is to assess the impact of COVID-19 on IBD patients in relation to pregnancy. Participation in this study will involve the completion of an one time, anonymous questionnaire online and the expected time involved is 15-20 minutes.

Who can participate? You can help us if you: 
1. Are considering pregnancy, are pregnant, or recently pregnant,
2. Are interested to provide your anonymous insight on the impact of COVID-19 on IBD and pregnancy.

If you are interested in completing the online survey, please enter this link into your web browser. https://ddcrc.mshri.on.ca/NoviSurvey/n/zzzsc.aspx

This study has been approved by the Mount Sinai Hospital Research Ethics Board (REB# 19-0310-E)

To find out more information about this study or to volunteer, please contact:
Email: HuangIBDclinic@sinaihealth.ca

Principal Investigator:  Dr. Vivian Huang 
Contact Information: 416-586-4800 ext 2475 

You are being invited to participate in a completely anonymous research study because you have had Inflammatory Bowel Disease (‘IBD’; either Crohn’s disease or Ulcerative Colitis) and may be contemplating pregnancy, are currently pregnant or have recently been pregnant. This survey is part of a larger registry study currently being conducted by Sinai Health System. 

The aim is to assess the thoughts of IBD patients, specifically surrounding pain management, IBD and pregnancy. Participation in this study will involve the completion of a anonymous questionnaire, either in person or online and the expected time involved is 15-20 minutes.

If you are interested in completing the online survey, please enter this link into your web browser. https://ddcrc.mshri.on.ca/NoviSurvey/n/zzzud.aspx

This study has been approved by the Mount Sinai Hospital Research Ethics Board (REB# 19-0309-E)

To find out more information about this study or to volunteer, please contact:
Email: HuangIBDclinic@sinaihealth.ca

Principal Investigator:  Dr. Vivian Huang 
Contact Information: 416-586-4800 ext 2475

Self-care has been linked to improving symptom management and quality of life for individuals with inflammatory bowel disease however; limited research has been conducted focusing on adults with inflammatory bowel disease and their meaning of self-care in Northeastern Ontario. Therefore, the purpose of this research will be to explore the lived experiences of adults with inflammatory bowel disease and their meaning of self-care in Northeastern Ontario to examine what self-care strategies improve quality of life and symptom management for this particular population.

Who can participate? You can help us if you: 
1. Live in Northern Ontario 
2. Have Crohn’s or ulcerative colitis for over 2 years
3. Do not have any other diseases of the digestive system (IBS, GERD, Celiac disease) 
4. Can speak and read English

This study has been approved by the Laurentian University Research Ethics Board (REB# 6020691)

If you agree to participate, you will be asked to complete an interview that will take approximately 1 hour of your time.

To find out more information about this study or to volunteer, please contact:
Kelsey Lefebvre (MSc Nursing Student)
Phone: 1-705-221-4909
Email: klefebvre@laurentian.ca

Supervisors:  Dr. Craig Duncan & Professor Irene Koren

Were you diagnosed with pediatric-onset Crohn’s disease or ulcerative colitis? Are you a parent or caregiver to someone transitioning from pediatric IBD care to adult IBD care? If so, we are interested in hearing from you! As part of research being conducted through our Promoting Access and Care through Centres of Excellence (PACE) Network (https://crohnsandcolitis.ca/PACE), Crohn’s and Colitis Canada will be conducting a series of 1 hour web-based focus groups to learn more about what you feel are important elements for transition care for adolescents with inflammatory bowel disease. For example, an important element for you might be establishing care in a centre able to provide comprehensive care; for someone else, it might be finding an adult provider close to home.

We’re hoping to generate some interesting and informative discussions that cover a range of aspects you think of when you reflect on how you are doing in terms of transitioning from pediatric to adult care, as you manage your Crohn’s disease or ulcerative colitis.

Date: Thursday, September 12, 2019
Time: 3-4 PM EST for young people living with Crohn’s or colitis
           4-5PM EST for parents/caregivers of young people living with Crohn’s or colitis
Location: Via webconference

OR

Date: Saturday, September 14, 2019
Time: 11AM-12PM EST for young people living with Crohn’s or colitis
           12-1PM EST for parents/caregivers of young people living with Crohn’s or colitis
Location: Via webconference

Please RSVP to Jacqueline de Guzman at jdeguzman@crohnsandcolitis.ca or by calling (416) 920-5035 ext. 234.

This initiative (#REB 2019-0106-E) was formally reviewed and approved by institutional authorities at Women’s College Hospital.

Principal Investigators:
Dr. Natasha Bollegala 
Division of Gastroenterology, Women’s College Hospital
Assistant Professor in the Department of Medicine, University of Toronto

Dr. Nancy Fu 
Clinical Assistant Professor University of British Columbia
Division of Gastroenterology, Richmond General Hospital
 

Canada has one of the highest reported incidence and prevalence rates of inflammatory bowel disease (IBD) in the world with 1 out of every 150 Canadians diagnosed with IBD. Some research shows higher than normal levels of hydrogen sulfide in people with UC and we want to try and decrease these levels using the food you eat. This may help improve how healthy your intestine is. 

We are doing this study to try and figure out if we can decrease the amount of hydrogen sulfide you produce in your gut and if this helps improve your UC over 8 weeks. We want to see if we can improve the well-being of patients by using a special diet. We will ask people with UC who are eligible to join the study meet with a registered dietitian (RD) who will help you design a diet that works for you and your life over the next 8 weeks. We will then compare people who change their diet to people who do not change their diet. We hope people who use the special diet will improve their ulcerative colitis.

Who can participate? You can help us if you: 
1. Patients 18 - 80years in Calgary
2. Able to provide informed consent 
3. Patients with ulcerative colitis (UC) who are experiencing a mild or moderate UC flare or UC in remission

We will need you to come to the clinic to meet with the study coordinator three times. Each patient will receive a $25 gift card to cover parking costs for visits to the Foothills. Each meeting will be for 30-50 minutes. At this meeting, you will be asked to fill out some surveys, do some blood work, a urine tests, and bring in a stool sample. 

This study has been approved by Conjoint Health Research Ethics Board (CHREB) at the University of Calgary (REB# 16-2491_REN3)

To find out more information about this study or to volunteer, please contact:

Research coordinator: Munazza Yousuf
Phone: 403-592-5231
Email: ascend@ucalgary.ca 

Principal Investigator:  Dr. Maitreyi Kothandaraman

Many patients with IBD believe diet impacts their symptoms and course of their disease. There are very few research studies that have looked at the impact of diet on IBD, so at the present time it is difficult for health professionals to provide nutrition advice based on scientific evidence. Very little is known about how diet in patients with IBD impacts symptoms, the immune system and the bacteria in the intestine. We are inviting YOU to join us in a study of diet in patients with UC. We want to find out if diet has an impact on symptoms, intestinal bacteria and the immune system in UC. 

Who can participate? You can help us if you: 
1. Are at least 18 years of age
2. Patients with ulcerative colitis (UC)

Study Sites: Kelowna (Okanagan area), Vancouver, Edmonton, Halifax

This study has been approved by The University of British Columbia Clinical Research Ethics Board (REB# H16-03300)

To find out more information about this study or to volunteer, please contact:

Research coordinator: Natasha Haskey
Phone: 778-583-1982
Email: natasha.haskey@ubc.ca

Principal Investigator: Dr. Deanna Gibson

Our project aims to understand the experience of transitioning from pediatric to adult care from the perspective of patients, caregivers, and health care providers. As a current or former pediatric patient with experience transitioning from pediatric to adult care or as a caregiver whose child is being cared for by at least one pediatric specialist or who has had a child transferred to adult care within the past 3 years, you are invited to participate in this study. 

Participation in this study involves attending a virtual focus group. During the focus group a research team member will ask you questions about your experience of and barriers and enablers to transitioning from pediatric to adult care. 

Participation in this study will take approximately one hour of your time. 

Who can participate? Participants in this study, must either be or have experience caring for a patient diagnosed with one of three conditions of focus: Inflammatory Bowel Disease, Diabetes, or Juvenile Idiopathic Rheumatoid Arthritis.

What is in it for you?
In appreciation of your time commitment, you will be offered a $ 25 gift card and invited to enter a draw to win 1 of 3 $100 Visa gift cards.

This study has been approved by IWK Research Ethics Board (Project #:1026111).

To find out more information about this study or to volunteer, please contact:

Research Assistant: Liam Rowe 
Email: Liam.Rowe@NSHealth.ca

Principal Investigator: Dr. Christine Cassidy (Dalhousie University) and Jackie Pidduck (IWK Health Centre)

Considering the changes to healthcare access that occurred during the pandemic and its potential impact, the goal of this study is to survey IBD patients and determine how the COVID-19 pandemic has affected their care. We will attempt to gauge whether there were any concerns with compliance with regards to medical treatments during this period of time, and patient factors that may have led to a lack of compliance. In doing so, we hope to ascertain whether telemedicine is an effective tool in providing follow up care when compared to in-person visits. 

We will also attempt to understand whether there was a change in the access to care that participants had during this period of time. This includes asking about hospital admissions, appointment cancellations, and ER visits. Lastly, through the feedback from IBD patients, we may be able to limit future barriers to care by acknowledging systemic and patient factors that delay access to investigations and therapies.

Who can participate?
1. Participants over the age of 18
2. Diagnosis of Crohn's Disease or Ulcerative Colitis

To participate, please click on the following link:
 https://redcap.lawsonresearch.ca/surveys/?s=HTKF7C4YY9

This study has been approved by The Western University Health Sciences Research Ethics Board (REB# 116407)

To find out more information about this study or to volunteer, please get in touch with:
Research Contact: Dr. Gurpreet Malhi
Email: gurpreet.malhi@lhsc.on.ca

Principal Investigator:  Dr. Aze Wilson

This study is part of a global research effort to follow IBD patients at infusion centers around the world. We will measure the baseline prevalence of SARS-CoV-2, the virus that causes COVID-19, exposure by antibody testing (involves taking a blood sample) and follow with scheduled testing (blood sample at each of the visits) every 8 weeks over a 48-week period.

Through analysis of clinical data and patients’ social behaviors(questionnaire), we will be able to identify social, treatment-related, and biological factors that determine whether patients acquire mild, asymptomatic, or severe disease. This study could lead to improvements in understanding the effects of medications and viral infections in IBD and help on future pandemic preparations and epidemiological studies.

Who can participate? 
1. Participants 18 years or older
2. Been diagnosed by your physician with IBD (Crohn’s Disease, Ulcerative Colitis, IBD-U)
3. Currently receiving treatment for IBD with Infliximab, other biologics or Vedolizumab
4. May or may not been diagnosed with COVID-19. 

This study has been approved by the Mount Sinai Hospital Research Ethics Board (REB# 20-0217-E)

To find out more information about this study or to volunteer, please get in touch with:

Research Coordinator: Raquel Milgrom
Email: Raquel.Milgrom@sinaihealth.ca

Principal Investigator:  Dr. Mark Silverberg

The objective of this study is to explore the impact the COVID-19 pandemic has had on gastroenterologists providing care to IBD patients in Canada. We aim to identify the affect the COVID-19 pandemic has had on clinical decision-making when implementing evidence-based medicine while managing inflammatory bowel disease patients. In addition, we aim to identify the delays and barriers inflammatory bowel disease patients experienced when accessing specialty gastroenterology consultation and follow-up appointments, laboratory and radiological investigations and endoscopic procedures in Canada during the COVID-19 pandemic. 

The findings of this study will help provide further information on how to support inflammatory bowel patients in the future.

Who can participate? 
1. Adult gastroenterologists (>18), with MD or MBBS degree, practicing in Canada
2. Have completed specialty training in Internal Medicine and Gastroenterology
3. Be able to provide informed consent

If you are interested, please enter this link into your web browser https://redcap.lawsonresearch.ca/surveys/?s=CEET7TLEYN

This study has been approved by The Western University Health Sciences Research Ethics Board (REB# 116360)

To find out more information about this study, please get in touch with:

Research Contact: Maria Mikail
Email: mmikail@uwo.ca​

Principal Investigator:  Dr. Aze Wilson

The purpose of this study is to obtain an understanding of perceived health-related quality of life (HRQOL) and care experiences in older adults with IBD. The objectives are to: 1) assess perceived HRQOL and chronic illness care in older adults with IBD; and 2) explore the care experiences of older adults with IBD living in Canada. The older adult age group is the fastest growing group of individuals with IBD and obtaining perspectives about older adult’s goals of care and how the care received impacts their quality of life are important considerations for future health service delivery plans. There is not a lot of information on the perspectives from older adults with IBD and our research team wants to increase knowledge in this area. 

This project is a 1 year study with 2 ways to participate (You can participate by selecting one or both options). 

1. An anonymous online or paper survey – The survey will take you about 20-40 minutes to complete. 

2. A confidential telephone or online interview - The research team is looking to conduct 30-60 minute interviews with older adult patients who have IBD. The interview questions will ask you about your IBD history and what it is like living with IBD as an older adult. 

Who can participate? You can help us if you: 
1. Have been diagnosed with Inflammatory Bowel Disease (IBD) (either Crohn’s Disease or Ulcerative Colitis). Diagnosis could have occurred at any age
2. Are currently 60 years of age or older. 
3. Are able to read and speak English fluently. 
4. Live in Canada 

If you are interested in completing the online the online survey, please enter this link into your web browser https://www.surveymonkey.ca/r/IBDolderadultCAN 

This study has been approved by the University of Saskatchewan Research Ethics Board (BEH#2341). 

To find out more information about the paper survey or telephone interview, please get in touch with:

Research Assistant: Ms. Brooke Russell
Email: brooke.russell@usask.ca

Principal Investigator:  Dr. Noelle Rohatinsky
Email: noelle.rohatinsky@usask.ca

Researchers at Deakin University together with Crohn’s & Colitis Australia are looking for adults with a diagnosis of IBD established by a gastroenterologist who are worried about the recent COVID-19 pandemic, to take part in a study to test an online / telephone writing intervention aiming to reduce worry associated with the COVID-19 pandemic.

This new study funded by Deakin University and Janssen Australia will assess whether the writing intervention improves mental health and quality of life compared with an active control group at post-intervention and 3 months post-intervention. 

Who can participate?
If you have IBD (Crohn’s disease, ulcerative colitis or indeterminate colitis) and can provide us with the details of your gastroenterologist, are 18 years of age or older, worry about the COVID-19 pandemic, communicate in English, and have access to the internet, you are eligible to participate. 
Please note that the study is addressed to people with mild to moderate levels of distress only. You will be screened for distress and if your level of distress is high, you will not be eligible for the study. You will then be provided with information where to seek mental health support.

This study has been approved by the Deakin University Human Research Ethics Committee (REB# 2020-122)

To find out more information about this study or to participate please get in touch with:

Research Contact: Bec Orr
Email: writeforibd@deakin.edu.au

Principal Investigator: Dr. Antonina Mikocka-Walus
Email: mikocka@deakin.edu.au

This study seeks to understand the perceptions of ostomy surgery in young women living with Inflammatory Bowel Disease (IBD) and the factors that influence their decision to have this surgery.

Who can participate?
(1) Identify as female
(2) Are between the ages of 19 and 30
(3) Currently live with an ostomy (for any length of time)

This study has been approved by the University of Victoria Human Research Ethics Board (REB# 18-1037)

To find out more information about this study or to participate please get in touch with:

Research Contact: Ashley Clark
Email: clarkash@uvic.ca

Principal Investigator: Dr. Andre Smith

The use of medical cannabis has received increasing attention for its potential role in inflammation and immune function for IBD. In this study, we explore patients' perceptions and experiences with cannabis to manage IBD symptoms and improve quality of life and disease outcomes. 

This survey is open to all patients with IBD who live in Saskatchewan. We would like to hear from everyone with IBD regardless of their personal history with cannabis. Everyone is welcome – those who are currently using cannabis products to those who have never used it before.

The research aims are to 1) develop a better understanding of cannabis use in IBD; 2) explore patient's experiences/beliefs on medical cannabis use for IBD, and to 3) improve outcomes for patients with IBD and ensure that medical cannabis is used safely and effectively. The survey will take 10-15 minutes to complete. 

Who can participate?
1) diagnosed with IBD; 
2) 18 years of age and older; 
3) residents of Saskatchewan.

If you’re interested in participating, you can access the survey here: https://www.surveymonkey.ca/r/IBDCBD

Participants who complete the survey will be entered to win a gift card, a 1 in 50 chance. 

This study has been approved by the University of Saskatchewan Behavioural Ethics Board (ID #1254).

To find out more information about this study please get in touch with:

Research Contact: Jennifer Chami
Email: ibd.cannabis@usask.ca
Telephone: 306-966-5104

Principal Investigator: Dr. Sharyle Fowler

The PediCRaFT (Pediatric CRohn’s Disease Fecal Microbiota Transplant) Trial is the first Health Canada approved fecal microbiota transplant (FMT) trial for children living with Crohn’s disease across Canada.

Study involves:
i) Colonoscopy (optional): Patients will have baseline disease severity assessed on endoscopy, and receive FMT infusion into the terminal ileum via colonoscopy. Initial baseline colonoscopy (supervised by pediatric anesthesia, endoscopy nurse, and pediatric gastroenterologist) through McMaster Children’s Hospital’s outpatient pediatric endoscopy suite..

ii) Rectal enema (optional): Patients may receive a rectal enema FMT infusion instead of colonoscopy, based on availability and patient preference. This is done through the McMaster Children’s Hospital outpatient Pediatric Gastroenterology & Nutrition clinic.

iii) Oral FMT Capsule (6 weeks): Twice per week, for 6 weeks, you will be given oral capsules that you may take at home. Capsules will contain healthy bacteria. 

Who is eligible?
Children ages 3 to 17 years old, diagnosed with Crohn’s disease or IBD-U. 

Study Requirements:
1.) Bloodwork
2.) Urine Samples
3.) Stool samples
4.) Complete a 6-Question survey

This study has been approved by the Hamilton Integrated Research Ethics Board (REB#4457)

To find out more information please get in touch with:

Research Contact: Lee Hill
Email: hill.lee.devlin@gmail.com
Telephone: 514-443-8488

Principal Investigator: Dr Nikhil Pai

We are looking for women with IBD who are in the preconception, pregnancy, or postpartum period to participate. 

Your role in this study
You will be asked to complete an online survey, which will be completed through Novi Survey, a secure online survey platform. The online survey should take approximately 30 minutes to complete. You will be asked to complete questions on demographics and Aspirin (side effects, potential benefits, etc.). 

Voluntary Participation and Confidentiality 
Your participation in this research study is completely voluntary. You may refuse to participate at any time, decline to answer any question, or withdraw from the study without any negative consequences. All information will remain anonymous and will be used for research purposes only (which includes publication). This study has been approved by Research Ethics at the University of Toronto. 

Potential Risks and Benefits 
There are no foreseeable risks involved in your participation in this research. Your participation will aid the study investigators in furthering our understanding of Aspirin prescribing in Preeclampsia prevention in women with IBD. There are no direct benefits to you.

This study has been approved by the Mount Sinai Hospital Research Ethics Board (REB#20-0263-E)

If you’re interested in participating, you can access the survey here: https://ddcrc.mshri.on.ca/NoviSurvey/n/zz13g.aspx

To find out more information please get in touch with:

Research Contact: Youstina Hanna
Email: youstina.hanna@mail.utoronto.ca
Telephone: 416-586-4800 ext 2677 

Principal Investigator: Dr. Vivian Huang

The purpose of this research is to better understand patients' preferences and decision-making around having a COVID-19 vaccine.

Who can participate?
Any adults (age 18+) with autoimmune conditions and/or taking immune suppressing medications. This includes conditions such as Crohn’s disease and Ulcerative colitis.

What would I have to do?
You will be asked to complete a one-time online survey, which should take you about 15 minutes. We will ask you some general questions about yourself and your condition, and questions about your thoughts and preferences for different COVID-19 vaccines. In part of the survey, we will ask you to review a selection of different COVID-19 vaccine options, and select whether or not you would choose the one shown.

To read the full consent form and participate, please visit https://bit.ly/3d2cALt

This study has been approved by the University of Calgary Conjoint Health Research Ethics Board (REB21-0080)

To find out more information please get in touch with:

Research Contact: Pauline Hull
Email: pauline.hull@ucalgary.ca

Principal Investigator: Dr. Glen Hazlewood
Email: gshazlew@ucalgary.ca

Many patients with IBD also have anxiety and mood disorders (AMDs); when present, AMDs conditions lead to a lower quality of life and increased symptom burden in persons with IBD. Despite this, symptoms of AMDs are not always reported by patients to their treating gastroenterologists, and gastroenterologists do not always inquire about AMDs in persons who are having symptoms related to their IBD.

We are trying to get a better sense of the perspectives of patients and gastroenterologists on why AMDs are not always addressed during a clinical assessment, and what can be done to better incorporate the identification and treatment of AMDs into routine gastroenterologic practice.

Focus group are a way to collect data on patient perceptions, experiences, and insights related to IBD care access. Focus groups provide more naturalistic interaction and may be more applicable to real-world settings into your perspectives.

Eligibility criteriaa:
You are invited to take part in this research study if you are a physician in community practice who treats patients with Inflammatory Bowel Disease (IBD)

This study has been approved by the Mount Sinai Hospital Research Ethics Board (REB# 19-0377-E)

To find out more information about this study or to participate please get in touch with:

Research Assistant: Ashley Patel
Email: ashley.patel@sinaihealth.ca

Principal Investigator:  Dr. Laura Targownik
Telephone: 416-586-4800 x 4304

This project aims to capture the modification of lifestyle habits, stress, anxiety levels and coping strategies and vaccination perception of immunosuppressed people and their relatives in the specific context of the confinement associated with COVID-19. 

We also wish to study the impact of pet ownership on lifestyle behaviours and mental health of this population. 

We conducted a first data collection during summer 2020 among 137 transplant recipients and their relatives to understand the impact of COVID-19 pandemic on lifestyle behaviours and mental health. We are now conducting a follow-up among these participants and recruiting new immunosuppressed participants (transplanted or not) and their relatives to investigate changes and current states in mental health and lifestyle behaviours one year after the start of COVID-19 pandemic.

Eligibility criteria:
Participants of all ages who are immunosuppressed for various reasons (transplant recipients, people suffering from autoimmune diseases, etc.) as well as their relatives.

This study has been approved by the Comité d'éthique de la recherche du CHUM (REB# 20.018)

If you’re interested in participating, you can access the survey here: https://survey.ca1.qualtrics.com/jfe/form/SV_1LaD8RziswKux6u

To find out more information please get in touch with:

Project Manager: Stéphanie Larivière
Email: stephanie.lariviere-beaudoin.chum@ssss.gouv.qc.ca

Principal Investigator:  Dr. Dr. Isabelle Doré 
Email: isabelle.dore@umontreal.ca

Co-Investigator: Dr. Mélanie Dieudé
Email: mdieude@cntrp.ca

 

The University of Alberta invites you (or your child) to learn more about a research study in which you (or your child) may be eligible to take part. Research studies help improve how we care for our patients and their families. Whether you take part or not, you will always receive the best available care. 

Researchers would like to learn more about how the COVID-19 vaccine will impact patients with digestive diseases who take medications that impact the immune system.

Who can participate? 
1. You (or your child) may qualify if the following apply: Never tested SARS-CoV-2 positive or diagnosed with COVID-19.

2. Diagnosis of ulcerative colitis, Crohn’s disease, autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) or OR received a liver transplant. 

3. Medical treatment with one of the following: Vedolizumab [Entyvio®], Infliximab [Remicade®, Inflectra®, Renflexis®, Avsola®, Remsima®, Flixabi®] Adalimumab (Humira®, Hadlima®, Hyrimoz®, Idacio®], Ustekinumab [Stelara®], Tofacitinib [Xeljanz®], Prednisone, Azathioprine [Imuran®], Mycophenolate Mofetil [CellCept®], Sirolimus [Rapamune®], Tacrolimus [Prograf®], Cyclosporine [Gengraf®, Neoral®, Sandimmune®], or OR Ursodeoxycholic acid [Urso®, Actigall®].

If you (or your child) plans to receive the Pfizer-BioNTech vaccine (Tozinameran or BNT162b2) and would like to learn more about your eligibility for this study, you are welcome to contact Raymond Odsen at raymond.odsen@ahs.ca or (780) 248-1035.

This study has been approved by the University of Alberta Research Ethics Board (REB#Pro00110062). 

To find out more information visit the study website or please get in touch with:

Research Contact: Raymond Odsen
Email: raymond.odsen@ahs.ca
Telephone: 780 248 1035

Principal Investigator:  Dr. Daniel Baumgart